ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
ctDNA can detect ERBB2 amplification in many, but not all, patients with ERBB2 amplification detected in tumor samples. ctDNA molecular response was associated with better survival, and ctDNA co-alterations may offer insights into mechanisms of intrinsic and acquired resistance.
Authors
- Ron Bose (ORCID: https://orcid.org/0000-0003-1977-8894)
- Christopher J. Sweeney (ORCID: https://orcid.org/0000-0002-0398-6018)
- Claire F. Friedman (ORCID: https://orcid.org/0000-0003-2621-8553)
- Charles Swanton (ORCID: https://orcid.org/0000-0002-4299-3018)
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- Carin R. Espenschied (ORCID: https://orcid.org/0000-0001-6108-7785)
- Kanwal P. S. Raghav (ORCID: https://orcid.org/0000-0003-1311-4173)
- Katja Schulze (ORCID: https://orcid.org/0000-0003-3704-5651)
- Julia Malato
- Jessica M. Grindheim (ORCID: https://orcid.org/0000-0003-2149-1622)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Howard A. Burris (ORCID: https://orcid.org/0000-0002-1501-2931)
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- Richard Price (ORCID: https://orcid.org/0000-0002-0069-5880)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Medical College of Wisconsin (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- The Francis Crick Institute (GB)
- Guardant (United States) (US)
- Sarah Cannon (US)
- Centre for Cancer Biology (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2763
- Citations
- 7
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- Roche
- Genentech